KLRK1 and neoplasm: To target NKG2D ligands present on the surface of tumor cells, we previously generated an NKG2D-based chimeric antigen receptor (termed NKAR), which is composed of an immunoglobulin heavy-chain signal peptide, the NKG2D extracellular domain followed by a flexible linker and a Myc-tag, connected to the transmembrane and intracellular domains of CD3ζ by a modified CD8α hinge region [27].